Patents Examined by Randall L Beane
-
Patent number: 11965001Abstract: Provided herein are thermomer monomer, thermomer dimers, thermomer monomeric constructs, thermomer dimeric complexes, and related gene expression cassette vectors, cells, surfaces devices, compositions methods and systems, that provide a thermobioswitch suitable to control location and/or binding of cargo moiety of interest in a temperature regulated manner.Type: GrantFiled: July 13, 2020Date of Patent: April 23, 2024Assignee: California Institute of TechnologyInventors: Dan I. Piraner, Mikhail Shapiro
-
Patent number: 11932667Abstract: Described herein are methods for the expression and purification of Cas13a and methods for detecting target RNA using Cas13a.Type: GrantFiled: February 25, 2021Date of Patent: March 19, 2024Assignee: INTEGRATED DNNA TECHNOLOGIES INC.Inventors: Sarah Franz Beaudoin, Michael Allen Collingwood, Christopher Anthony Vakulskas, Mark Aaron Behlke
-
Patent number: 11918625Abstract: Interferon-?-inducible protein 10 (IP-10) peptides, IP-10 peptide variants and in silico designed C-X-C chemokine receptor 3 (CXCR3) peptide agonists are described. The small peptides can be used for inhibiting pathological tissue remodeling and treating fibrosis in a subject, such as a subject with fibrosis of the heart, lung, liver, kidney or skin. The peptide agonists can also be used to treat cardiovascular disease, including myocardial infarction and ischemia-reperfusion injury. Also described are in silico designed peptide antagonists that bind CXCR3 or ligands of CXCR3. These antagonist peptides block CXCR3 signaling by disrupting interaction of CXCR3 with its ligand. Antagonist peptides can be used, for example, to treat myocarditis and atherosclerosis. In additional embodiments agonists and antagonists of CXCR4 are disclosed.Type: GrantFiled: April 20, 2022Date of Patent: March 5, 2024Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Tuskegee UniversityInventors: Cecelia C. Yates-Binder, Jesse Jaynes
-
Patent number: 11918624Abstract: It is disclosed a therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders, wherein the therapeutic composition comprises at least one active agent being selected from the following active agent groups a) to e): a) complement factor 3-targeting inhibitor of complement activation cascade b) carboxypeptidase B enzyme c) complement factor 5a receptor-targeting inhibitor of complement activation cascade d) endothelin A receptor-targeting inhibitor of extravasation e) bone morphogenic protein. It is further disclosed a method of treating COVID-19 and other cytokine storm associated disorders, wherein said method comprises administering an effective amount of at least one active agent being selected from the above mentioned active agent groups a) to e).Type: GrantFiled: June 10, 2020Date of Patent: March 5, 2024Assignee: Kelsius Laboratories LLCInventor: Lajos Baranyi
-
Patent number: 11891421Abstract: The present invention relates to a variant of BPIFB4 protein (Bactericidal/Permeability Increasing protein family B, member 4) and to a polynucleotide or a vector encoding said variant of BPIFB4 protein and to their use for the treatment of pathologies involving impairment of nitric oxide signalling.Type: GrantFiled: November 12, 2021Date of Patent: February 6, 2024Assignee: LGVI S.R.L.Inventors: Annibale Alessandro Puca, Carmine Vecchione
-
Patent number: 11857610Abstract: This disclosure relates to methods for preventing or reducing the risk of development of graft versus host disease (GVHD) in patients receiving hematopoietic cell transplantation (HCT) by particular methods of administering alpha-1 antitrypsin (A1AT or AAT) to patients both prior to and following and HCT procedure. The disclosure also relates to specific methods of treating acute GVHD (aGVHD) after HCT with A1AT.Type: GrantFiled: November 30, 2018Date of Patent: January 2, 2024Assignee: CSL Behring LLCInventors: Marc Uknis, Christine Voigt, Gautam Baheti, John Roberts
-
Patent number: 11820835Abstract: The present technology provides compounds of Formula I (or pharmaceutically acceptable salts and/or solvates thereof) that are useful in treating a CNS-related disorder such as schizophrenia, schizoaffective disorder, migraine, depression, pain, drug addiction, drug use, and/or drug seeking behavior. Also provided are compositions, medicaments, and methods including such compounds.Type: GrantFiled: March 22, 2019Date of Patent: November 21, 2023Assignees: UNIVERSITY OF KANSAS, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Jane Aldrich, Sanjeewa Senadheera, Jay McLaughlin
-
Patent number: 11793861Abstract: The present invention relates to PTH prodrugs, pharmaceutical compositions comprising such PTH prodrugs and their uses.Type: GrantFiled: November 8, 2022Date of Patent: October 24, 2023Assignee: ASCENDIS PHARMA BONE DISEASES A/SInventors: Kennett Sprogøe, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
-
Patent number: 11760780Abstract: Methods are provided for identifying an agent that directly modulates a Bcl-2-associated x-protein (BAX) by promoting or disrupting dimerization of the BAX. Agents that directly modulate BAX by affecting dimerization are also provided.Type: GrantFiled: March 19, 2019Date of Patent: September 19, 2023Assignee: Albert Einstein College of MedicineInventor: Evripidis Gavathiotis
-
Patent number: 11739130Abstract: The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. In an exemplary embodiment, a method is disclosed that involves administering an expression vector that delivers a secretable and cell penetrating CARD to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization.Type: GrantFiled: March 17, 2021Date of Patent: August 29, 2023Assignee: University of Florida Research Foundation, IncorporatedInventors: Cristhian J. Ildefonso, Alfred S. Lewin, Qiuhong Li
-
Patent number: 11732001Abstract: The invention relates to a polypeptide comprising an amino acid having a bicyclo[6.1.0]non-4-yn-9-ylmethanol (BCN) group, particularly when said BCN group is present as: a residue of a lysine amino acid. The invention also relates to a method of producing a polypeptide comprising a BCN group, said method comprising genetically incorporating an amino acid comprising a BCN group into a polypeptide. The invention also relates to an amino acid comprising bicyclo[6.1.0]non-4-yn-9-ylmethanol (BCN), particularly and amino acid which is bicyclo[6.1.0]non-4-yn-9-ylmethanol (BCN) lysine. In addition the invention relates to a PylRS tRNA synthetase comprising the mutations Y271M, L274G and C313A.Type: GrantFiled: May 12, 2020Date of Patent: August 22, 2023Assignee: United Kingdom Research and InnovationInventors: Jason Chin, Kathrin Lang
-
Patent number: 11725032Abstract: There is described a nucleic acid molecule comprising a nucleotide sequence encoding a functional dystrophin protein. Also described is a vector, a host cell and a pharmaceutical composition comprising the nucleic acid molecule; use of the nucleic acid molecule in therapy, such as in the treatment of a muscular dystrophy; and a method of treating muscular dystrophy, the method comprising administering a therapeutically effective amount of the nucleic acid molecule to a patient suffering from a muscular dystrophy.Type: GrantFiled: December 5, 2018Date of Patent: August 15, 2023Assignee: Royal Holloway And Bedford New CollegeInventors: George Dickson, Linda Popplewell
-
Patent number: 11708393Abstract: A probe for imaging EGFR expressing cells includes an EGFR targeting moiety, a reporter moiety, and a hydrophilic linker that links the EGFR targeting moiety to the reporter moiety. The hydrophilic linker enhances solubility of the probe in an aqueous media as well as binding affinity of the probe to EGFR expressing cells.Type: GrantFiled: April 7, 2021Date of Patent: July 25, 2023Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: James P. Basilion, Richard Agnes
-
Patent number: 11702454Abstract: The present invention belongs to the field of biotechnology, in particular to a multivalent fusion protein AB-NAC-189, method for producing the same, and uses thereof. The protein AB-NAC-189 is a fusion of a polypeptide segment AB, nascent polypeptide-associated complex (NAC), and a protein 189 corresponding to amino acids 1-189 from the N-terminal of protein HarpinEa. The fusion has the properties of a multivalent plant immune protein, thus it can effectively stimulate the hypersensitive response of tobacco leaves and has good thermal stability. While stimulating the immune response of plants, it can also improve the disease resistance of plants and promote plant growth. The AB-NAC-189 multivalent vaccine shows higher activity per unit concentration, and greater ability to promote growth of wheat and tobacco; meanwhile it can significantly promote chlorophyll synthesis in Goji berry, thereby improving the yield and quality of Goji berries.Type: GrantFiled: October 17, 2021Date of Patent: July 18, 2023Assignee: Suzhou Yishuimo Biological Technology Co., LTDInventors: Aiyou Sun, Zhong Wang, Zengying Cai, Qun Yu, Zhiwei Li, Bing Sun, Chong Zhang, Shiyue Miao
-
Patent number: 11673970Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: GrantFiled: October 23, 2020Date of Patent: June 13, 2023Assignee: Silver Creek Pharmaceuticals, Inc.Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
-
Patent number: 11667674Abstract: Cyclic lipopeptides having one or more modifications relative to daptomycin, and methods of making them are provided. The cyclic lipopeptides can be used as antibacterial agents. The daptomycin analogues are generated by chemical synthesis, which makes introduction of an unnatural amino acid and any modification into daptomycin possible. Pharmaceutical compositions and method of use thereof for the disclosed daptomycin analogues are also provided.Type: GrantFiled: March 24, 2017Date of Patent: June 6, 2023Assignee: VERSITECH LIMITEDInventors: Xuechen Li, Hoi Yee Chow
-
Patent number: 11572398Abstract: The invention relates to a derivative of a GLP-1 analogue of a general Formula I, which derivative comprises a side chain attached to a Lys residue at position 34, 35, 36, 37, or 38 of the GLP-1 analogue, which side chain comprises a Branched linker, a 1st and a 2nd Protractor selected from C18 diacid, C20 diacid, and sulfonic acid C16, and at least one Linker element-1 incorporating ethylene glycol units. Linker element-1 may be incorporated in an optional Pre-linker, and/or in a 1st or 2nd Post-linker. The invention also relates to novel GLP-1 analogues, novel side chain intermediate products and their manufacture and use to prepare derivatives of biologically active peptides and proteins, as well as pharmaceutical compositions and medical uses of the analogues and derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.Type: GrantFiled: November 26, 2015Date of Patent: February 7, 2023Assignee: Novo Nordisk A/SInventors: Per Sauerberg, Jacob Kofoed
-
Patent number: 11566044Abstract: There is provided a range of novel disulfide bond containing compounds. These disulfide bond containing compounds can be used in a variety of applications such as solid phase peptide synthesis, solid phase organic synthesis, formation of dendrimers, formation of macromolecules and formation cyclic peptides; and as a component of a delivery vehicle with a bioactive molecule.Type: GrantFiled: July 26, 2018Date of Patent: January 31, 2023Assignee: THE UNIVERSITY OF QUEENSLANDInventors: Harendra Parekh, Karnaker Reddy Tupally
-
Patent number: 11518788Abstract: The disclosure provides recombinant polypeptides for treating or preventing viral infection comprising an immunoglobulin Fc fragment and at least one viral receptor or fragment thereof. Also provided are RNA molecules, therapeutic compositions, and expression systems comprising such recombinant polypeptides, along with methods of preventing or treating a viral infection in a subject in need thereof, comprising administering such recombinant polypeptides to a subject or patient.Type: GrantFiled: April 30, 2021Date of Patent: December 6, 2022Assignee: AVIRUS, INC.Inventors: Jang Hyun Han, William J. Rutter, Mi-Young Seo
-
Patent number: 11471513Abstract: A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin ?-subunit carboxyl terminal peptide, and a half-life extending portion (preferentially selected from a human IgG Fc variant). The fusion protein has a similar level of biological activity as a recombinant (FVIII) and an extended in vivo half-life, thereby improving pharmacokinetics and drug efficacy.Type: GrantFiled: November 16, 2016Date of Patent: October 18, 2022Assignees: Ampsource Biopharma Shanghai Inc., Furen Pharmaceutical Group Co., Ltd, Pharmab, Inc., Kaifeng Pharmaceutical (Group) Co., Ltd.Inventors: Qiang Li, Wenchen Zhu, Yuanli Li, Chenggong Zhu, Yongjuan Gao, Zijia Ren, Luyan Zhu, Naichao Sun, Xiaoshan Wang, Bin Liu, Zhi Li, Wenwen Wang, Ming Jiang, Qilei Wang, Lirui Wang, Shuya Wang, Songlin Zhu, Jie Gao, Hongsheng Su